Estonia - Estonian - Ravimiamet

gp-pharm s.a. - oktreotiid - süstelahus - 500mcg 1ml 1ml 5tk

Estonia - Estonian - Ravimiamet

bioveta a.s. - küülikute müksomatoosi elusviirusvaktsiin - süstesuspensiooni lüofilisaat ja lahusti - 10000tcid50 1annus 1annus 5tk; 10000tcid50 1annus 1annus 10tk; 10000tcid50 1annus 10annus 1tk; 10000tcid50 1annus 1annus 1tk; 10000tcid50 1annus 40annus 1tk; 10000tcid50 1annus 100annus 1tk; 10000tcid50 1annus 50annus 1tk; 10000tcid50 1annus 50annus 5tk; 10000tcid50 1annus 40annus 5tk; 10000tcid50 1annus 100annus 5tk; 10000tcid50 1annus 10annus 5tk; 10000tcid50 1annus 80annus 5tk; 10000tcid50 1annus 80annus 1tk

Estonia - Estonian - Ravimiamet

novartis baltics sia - oktreotiid - süste-/infusioonilahus - 0,1mg 1ml 1ml 10tk; 0,1mg 1ml 1ml 6tk; 0,1mg 1ml 1ml 3tk; 0,1mg 1ml 1ml 20tk; 0,1mg 1ml 1ml 5tk

European Union - Estonian - EMA (European Medicines Agency)

tetris pharma b.v - glucagon - diabeet mellitus - pankrease hormoonid, hormoonid glycogenolytic - ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.

European Union - Estonian - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

European Union - Estonian - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).

European Union - Estonian - EMA (European Medicines Agency)

astrazeneca ab - saxagliptin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - add-on combination therapyonglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

European Union - Estonian - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).

European Union - Estonian - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - linagliptiin - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - trajenta on näidustatud ravi 2. tüüpi suhkurtõve parandada glycaemic kontrolli täiskasvanud:kui monotherapyin patsientidel, ebapiisavalt kontrollitud dieet ja füüsiline koormus üksi ning kellele metformiin ei sobi tõttu, sallimatus, või vastunäidustatud tingitud neerupuudulikkus;. kui koostisega therapyin koos metformiin, kui dieedi ja füüsilise koormuse pluss metformiin üksi ei taga piisavat kontrolli glycaemic. koos sulphonylurea ja metformiin, kui dieedi ja füüsilise koormuse pluss dual ravi nende ravimitega ei taga piisavat kontrolli glycaemic. koos insuliini või ilma metformiin, kui seda raviskeemi üksi, koos dieedi ja füüsilise koormuse, ei anna adekvaatset kontrolli glycaemic.

Estonia - Estonian - Ravimiamet

galenicum health s.l.u. - vildagliptiin - tablett - 50mg 30tk; 50mg 336tk; 50mg 90tk; 50mg 112tk; 50mg 180tk; 50mg 60tk